Welcome to our dedicated page for Lilly Eli & news (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Lilly Eli & stock.
Eli Lilly & Co. develops and commercializes medicines across cardiometabolic disease, oncology, immunology, neuroscience and genetic medicine. Company news commonly covers product and pipeline developments for medicines such as Mounjaro, Zepbound, Foundayo, Omvoh, Verzenio, Jaypirca and Taltz, including clinical data, regulatory approvals and treatment-indication updates.
Lilly updates also include operating results, financial guidance, dividends, business development agreements and manufacturing expansion. Recent company communications highlight investment in active pharmaceutical ingredient capacity and genetic medicine production, alongside recurring disclosures about demand for diabetes, obesity, immune-disease and cancer therapies.
Lilly (NYSE: LLY) reported Phase 3 ACHIEVE data for oral GLP-1 Foundayo (orforglipron) in type 2 diabetes. Foundayo achieved larger A1C reductions and greater weight loss than oral semaglutide, dapagliflozin and placebo, with up to 2.2% A1C drops and 19.7 lbs weight loss.
Lilly plans a U.S. FDA submission for type 2 diabetes by the end of the second quarter, using a National Priority Review Voucher. According to Lilly, cardiovascular risk markers and safety were consistent with prior studies, with mainly gastrointestinal side effects.
Eli Lilly (NYSE: LLY) reported post-hoc results from ATTAIN-1 and ATTAIN-2 showing that women with obesity or overweight taking the highest dose of Foundayo (orforglipron), an oral GLP-1 taken without food or water restrictions, had significant weight loss at all menopause stages over 72 weeks.
Women lost up to 30.4 lbs (14.4%) in perimenopause and up to 28.2 lbs (14.1%) post-menopause in ATTAIN-1, and up to 27.8 lbs (13.6%) post-menopause in ATTAIN-2, with notable reductions in waist circumference and high proportions achieving ≥15% weight loss.
Lilly (NYSE:LLY) reported Phase 3 data for investigational triple agonist retatrutide in obesity, type 2 diabetes, knee osteoarthritis pain, and obstructive sleep apnea.
Across TRIUMPH-1 and TRANSCEND-T2D-1, retatrutide produced large average weight losses (up to 28.3%), A1C reductions up to 2.0%, and broad cardiometabolic risk-factor improvements, with gastrointestinal side effects common but mostly mild to moderate.
Lilly (NYSE: LLY) will highlight its expanding hematology portfolio at the 2026 European Hematology Association (EHA) Annual Meeting in Stockholm, June 11-14.
Key presentations cover Phase 3 BRUIN CLL-322 data for Jaypirca in relapsed/refractory CLL/SLL, plus early-stage programs from Ajax Therapeutics and Kelonia Therapeutics, which Lilly has agreed to acquire.
Lilly (NYSE: LLY) reported Phase 3 LIBRETTO-432 results for Retevmo (selpercatinib) as adjuvant therapy in early-stage RET fusion-positive NSCLC. Selpercatinib cut risk of disease recurrence or death by 83% versus placebo (HR 0.17; p<0.001) and improved 24‑month event-free survival.
Eli Lilly (NYSE: LLY) announced that all three of the largest U.S. PBMs will cover its full obesity medicine portfolio, Foundayo and Zepbound, expanding access to FDA-approved treatments.
CVS Caremark coverage for Foundayo starts June 1, 2026, with broader Zepbound coverage by October 1. Eligible commercially insured patients may pay as low as $25 per month, while certain Medicare Part D beneficiaries may pay $50 per month via the GLP-1 Bridge program starting July 1.
Eli Lilly (NYSE:LLY) will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. Kenneth Custer, executive vice president and president, Lilly Cardiometabolic Health, will join a fireside chat at 3:20 p.m. Eastern time.
A live audio webcast and a 90-day replay will be available on Lilly's investor website in the Webcasts & Presentations section.
Lilly (NYSE:LLY) agreed to acquire three companies—Curevo, LimmaTech Biologics and Vaccine Company—to expand its infectious disease portfolio focused on prevention.
Deals include up to $1.5B for Curevo, $780M for LimmaTech and $1.55B for Vaccine Company, adding late-stage shingles, early-stage bacterial and preclinical viral vaccine platforms.
Lilly (NYSE: LLY) reported interim Phase 1b Heart-2 data for VERVE-102, an investigational in vivo base editor targeting PCSK9 in adults with HeFH or premature CAD. In 35 participants, a single intravenous dose produced dose-dependent mean PCSK9 reductions of 51–88% and LDL-C reductions up to 62%, sustained for up to 18 months. VERVE-102 was reported as well tolerated, with no treatment-related serious adverse events or dose-limiting toxicities. The FDA granted Fast Track designation for VERVE-102 in hyperlipidemia with high cardiovascular risk, and Lilly plans to start a Phase 2 study by year-end.
Lilly (NYSE:LLY) will showcase an extensive oncology portfolio at the 2026 ASCO Annual Meeting from May 29–June 2 in Chicago. Highlights include Plenary Session presentations on Phase 3 data for Retevmo in RET fusion-positive NSCLC and Verzenio in advanced dedifferentiated liposarcoma.
Additional sessions feature first clinical results for an investigational Nectin-4–targeting ADC, multiple lung and blood cancer programs, and updated Phase 1 data on KLN-1010, an in vivo BCMA CAR-T from Kelonia Therapeutics, which Lilly has agreed to acquire, pending customary approvals.